AKYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Akoya Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.
For the Medical Instruments & Supplies subindustry, Akoya Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:
* The bar in red indicates where Akoya Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.
Akoya Biosciences (NAS:AKYA) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation
EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Thank you for viewing the detailed overview of Akoya Biosciences's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Mckelligon | director, officer: President/CEO | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Frederic Pla | officer: Chief Operating Officer | C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700 |
Goldman Myla Lai | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
John Frederick Ek | officer: Chief Financial Officer | 5964 LA PLACE COURT, CARLSBAD CA 92008 |
Scott Mendel | director | 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008 |
Matthew Winkler | director | C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744 |
Thomas A. Raffin | director, 10 percent owner | C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010 |
Robert G Shepler | director | |
Jennifer Kamocsay | officer: General Counsel | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762 |
Joseph Driscoll | officer: Chief Financial Officer | 5 DICARLO ROAD, HOPKINTON MA 01748 |
Nolan Garry Ph.d. | director | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Thomas P Schnettler | director | 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020 |
Ehab El-gabry | officer: Chief Medical Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Marilee Moy | officer: Chief People Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
Ramachandran Niro Ph.d | officer: Chief Business Officer | 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752 |
From GuruFocus
By Marketwired • 10-17-2023
By Tiesvg Tiesvg • 12-28-2022
By GuruFocus Research • 11-08-2023
By GlobeNewswire GlobeNewswire • 01-08-2023
By GuruFocus Research • 06-13-2023
By GlobeNewswire • 01-07-2024
By Marketwired • 11-02-2023
By Value_Insider Value_Insider • 12-15-2022
By Marketwired • 07-12-2023
By sperokesalga sperokesalga • 06-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.